Literature DB >> 31816483

Mortalities of methamphetamine, opioid, and ketamine abusers in Shanghai and Wuhan, China.

Feng Li1, Jinchen Liu2, Paul S F Yip3, Xuesong Lu4, Sihai Liu5.   

Abstract

Studies on the mortalities of drug abusers in China are scarce. This study explores the deaths of methamphetamine, opioid, and ketamine abusers in Shanghai (2004-2017) and Wuhan (2005-2017). Chi-square/Fisher's exact tests were used to compare the differences in terms of region, gender, age, cause of death, and the method used in the last drug abuse. Poisson regression models were used to estimate the rate ratios ("RRs") and annual percentage changes ("APCs"). 314 heroin, 43 methamphetamine, and 4 ketamine abusers were included. Furthermore, simultaneously, 6 abusers used heroin and methamphetamine, and 7 abusers used methamphetamine and ketamine. Heroin-related deaths have declined in Shanghai (APC, -16.1; 95 % CI, -18.4 to -11.3) and Wuhan (APC, -16.0; 95 % CI, -18.9 to -10.6), whereas methamphetamine-related deaths have increased in Wuhan (APC, 12.8; 95 % CI, 0.0 to 29.2). On the whole, in the two cities, males were more frequently observed than females in heroin-related deaths (4.4, 230/52). However, the gender ratios for methamphetamine- (1.8, 34/19) and ketamine-related deaths (1.2, 6/5) were close to one. In view of the mortality rates of the drug abusers in most Chinese cities were still unclear, it is thus important to improve mortality surveillance of the drug abusers at the national level.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Heroin; Ketamine; Methamphetamine; Mortality

Year:  2019        PMID: 31816483     DOI: 10.1016/j.forsciint.2019.110093

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  1 in total

1.  Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997-2019.

Authors:  John Martin Corkery; Wan-Chu Hung; Hugh Claridge; Christine Goodair; Caroline S Copeland; Fabrizio Schifano
Journal:  J Psychopharmacol       Date:  2021-06-05       Impact factor: 4.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.